Lv51
1160 积分 2026-03-04 加入
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
24天前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
24天前
已完结
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial
1个月前
已关闭
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
1个月前
已完结
PT2.13.01 A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC
1个月前
已完结
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
3个月前
已完结
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
4个月前
已完结
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as f irst-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
